Asset Details
Do you wish to reserve the book?
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma
Do you wish to request the book?
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma
2024
Overview
In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell–engaging antibody molecule (TEAM). Treatment with CARv3-TEAM-E T cells did not result in adverse events greater than grade 3 or dose-limiting toxic effects. Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants. (Funded by Gateway for Cancer Research and others; INCIPIENT ClinicalTrials.gov number,
NCT05660369
.)
A novel CAR T-cell therapy directed at EGFRvIII with a secretable EGFR T-cell engager produced rapid responses in three patients with recurrent glioblastoma, but the responses were transient in two of the three.
Publisher
Massachusetts Medical Society
Subject
/ Antigens
/ Biopsy
/ CD8-Positive T-Lymphocytes - metabolism
/ Epidermal growth factor receptors
/ ErbB Receptors - antagonists & inhibitors
/ Genetics
/ Glioma
/ Humans
/ Immunotherapy, Adoptive - adverse effects
/ Neoplasm Recurrence, Local - therapy
/ Oncology
/ Receptors, Antigen, T-Cell - genetics
/ Receptors, Antigen, T-Cell - therapeutic use
/ Receptors, Chimeric Antigen - therapeutic use
/ T-Cells
/ Teams
/ Toxicity
/ Tumors
